Evaluation of Ubiquinol on Mitochondrial Oxidative Capacity in Statin Patients Using 31PMRS
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
It is our primary hypothesis that statin drugs impair skeletal muscle mitochondrial function
and that ubiquinol (the reduced active form of CoQ10) supplementation will block impairment
of PCr recovery kinetics in patients using statins. The investigators propose a pilot study
to extend our research to examine PCr recovery kinetics in 20 statin users randomized in a
parallel arm study to either ubiquinol or placebo over 4 weeks.